JP2023529611A5 - - Google Patents

Info

Publication number
JP2023529611A5
JP2023529611A5 JP2022574164A JP2022574164A JP2023529611A5 JP 2023529611 A5 JP2023529611 A5 JP 2023529611A5 JP 2022574164 A JP2022574164 A JP 2022574164A JP 2022574164 A JP2022574164 A JP 2022574164A JP 2023529611 A5 JP2023529611 A5 JP 2023529611A5
Authority
JP
Japan
Prior art keywords
domain
fusion protein
nuclease
terminus
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529611A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035244 external-priority patent/WO2021247570A2/en
Publication of JP2023529611A publication Critical patent/JP2023529611A/ja
Publication of JP2023529611A5 publication Critical patent/JP2023529611A5/ja
Pending legal-status Critical Current

Links

JP2022574164A 2020-06-02 2021-06-01 ゲノム編集のための組成物及び方法 Pending JP2023529611A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063033397P 2020-06-02 2020-06-02
US63/033,397 2020-06-02
US202063114850P 2020-11-17 2020-11-17
US63/114,850 2020-11-17
US202163171698P 2021-04-07 2021-04-07
US63/171,698 2021-04-07
PCT/US2021/035244 WO2021247570A2 (en) 2020-06-02 2021-06-01 Compositions and methods for gene editing

Publications (2)

Publication Number Publication Date
JP2023529611A JP2023529611A (ja) 2023-07-11
JP2023529611A5 true JP2023529611A5 (enExample) 2024-06-10

Family

ID=78831704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574164A Pending JP2023529611A (ja) 2020-06-02 2021-06-01 ゲノム編集のための組成物及び方法

Country Status (10)

Country Link
US (1) US20240309345A1 (enExample)
EP (1) EP4158009A4 (enExample)
JP (1) JP2023529611A (enExample)
KR (1) KR20230031832A (enExample)
AU (2) AU2021283185A1 (enExample)
CA (1) CA3184884A1 (enExample)
GB (2) GB2637278B (enExample)
IL (1) IL298434A (enExample)
MX (1) MX2022015277A (enExample)
WO (1) WO2021247570A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
US20240254483A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
IL311610A (en) 2021-09-21 2024-05-01 Scribe Therapeutics Inc Engineered CASX suppressor systems
CN119836432A (zh) * 2022-05-01 2025-04-15 恩科洛玛生物公司 用于pcsk9表达的表观遗传调节的组合物和方法
CN119998446A (zh) 2022-06-07 2025-05-13 斯克里贝治疗公司 用于靶向pcsk9的组合物和方法
EP4544058A1 (en) * 2022-06-23 2025-04-30 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of ciita expression
KR20250059560A (ko) * 2022-06-23 2025-05-02 크로마 메디슨, 인크. 후성유전학적 편집을 위한 조성물 및 방법
WO2023250148A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic editing
WO2023250490A1 (en) * 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of trac expression
CA3260237A1 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
CA3260110A1 (en) 2022-06-24 2023-12-28 European Molecular Biology Laboratory MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI
EP4554967A2 (en) 2022-07-12 2025-05-21 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
JP2025526073A (ja) * 2022-08-11 2025-08-07 エピジェニック・セラピューティクス・プライベイト・リミテッド エピジェネティック編集標的部位のための方法およびその使用
WO2024032681A1 (zh) * 2022-08-11 2024-02-15 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
WO2024040254A2 (en) * 2022-08-19 2024-02-22 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
WO2024044574A1 (en) * 2022-08-23 2024-02-29 The Regents Of The University Of California Compositions and methods for reducing ionizing radiation-induced hematopoietic stem cell damage
JP2025531268A (ja) 2022-09-19 2025-09-19 チューン セラピューティクス インコーポレイテッド Ｔ細胞機能を調節するための組成物、システム、および方法
KR20250110209A (ko) * 2022-09-23 2025-07-18 엔크로마 바이오, 인크. Hbv 유전자 발현의 에피제네틱 조절을 위한 조성물 및 방법
WO2024081879A1 (en) * 2022-10-14 2024-04-18 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of cd247 expression
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
JP2026506083A (ja) 2023-02-17 2026-02-20 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ エピジェネティック修飾を行うための組成物および方法
WO2024238321A1 (en) * 2023-05-12 2024-11-21 Mammoth Biosciences, Inc. Compositions and methods for targeted epigenetic modification
JP2026523341A (ja) 2023-05-15 2026-07-14 エヌクロマ・バイオ，インコーポレーテッド Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法
TW202503061A (zh) * 2023-06-16 2025-01-16 大陸商益杰立科（上海）生物科技有限公司 靶向ｂ型肝炎病毒基因的表觀編輯工具
CN121909284A (zh) 2023-07-31 2026-04-21 图恩疗法股份有限公司 用于调节il-2基因表达的组合物和方法
EP4754248A1 (en) 2023-07-31 2026-06-10 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025251019A1 (en) * 2024-05-31 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic editing
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
WO2026064753A1 (en) 2024-09-23 2026-03-26 Tune Therapeutics, Inc. Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
WO2026102058A1 (en) 2024-11-06 2026-05-15 Tune Therapeutics, Inc. Methods for treating chronic hepatitis b infection and related formulations
WO2026161895A1 (en) 2025-01-27 2026-07-30 Tune Therapeutics, Inc. Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015298571B2 (en) * 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3443081A4 (en) * 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
US11286493B2 (en) * 2016-05-27 2022-03-29 The Regents Of The University Of California Methods and compositions for targeting RNA polymerases and non-coding RNA biogenesis to specific loci
AU2019255789B2 (en) * 2018-04-19 2025-11-20 The Regents Of The University Of California Compositions and methods for gene editing

Similar Documents

Publication Publication Date Title
GB2612212A (en) Compositions and methods for gene editing
JP2023506765A5 (enExample)
JP2021506814A5 (enExample)
Pause et al. The HRIGRXXR region of the DEAD box RNA helicase eukaryotic translation initiation factor 4A is required for RNA binding and ATP hydrolysis
JP2024083479A5 (enExample)
Tung et al. Preparation and applications of peptide− oligonucleotide conjugates
JP2021521833A5 (enExample)
JP2024535672A5 (enExample)
JP2022513141A5 (enExample)
JPWO2019156137A5 (enExample)
JPH02211879A (ja) ヒトインターフエロンβ２のｃＤＮＡ及びその製造法
JP2023529844A5 (enExample)
US11066448B2 (en) Zika as a cell penetrating peptide for delivery to the brain
JP2024511131A5 (enExample)
CN106279439A (zh) 一种含有穿膜肽的寡肽‑1融合蛋白及其制备方法
US20140303071A1 (en) Cyclic antimicrobial peptides
JP2024529425A5 (enExample)
JP2024516613A5 (enExample)
JP2024503091A5 (enExample)
GB2612466A (en) Compositions and methods for epigenome editing
CN106480070B (zh) 一种用于展示目的多肽的多肽载体及其用途
JPS6270397A (ja) 水痘−帯状疱疹ウイルスにたいするワクチン
DE69131624T2 (de) Peptidzusammensetzung aus pseudomonas und methode diese herzustellen
JP2018533908A5 (enExample)
US4743553A (en) Synthetic genes for bovine parainfluenza virus